SCHEMBL27213203

SCHEMBL27213203

Cc1sc(-c2nc(NC3CCN(S(=O)(=O)c4cnn(C)c4)CC3)ncc2C(F)(F)F)cc1C#N

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 20/20 0.61
▸ CCNE1 P24864 19/20 0.61
▸ CDK1 P06493 15/20 0.61
▸ CCNB1 P14635 15/20 0.61
▸ CDK4 P11802 13/20 0.61
▸ CCND1 P24385 13/20 0.61
▸ CCND3 P30281 13/20 0.61
▸ CDK6 Q00534 13/20 0.61
▸ CCNT1 O60563 7/20 0.61
▸ CDK7 P50613 7/20 0.61
▸ CDK9 P50750 7/20 0.61
▸ CCNH P51946 7/20 0.61
▸ MNAT1 P51948 7/20 0.61
▸ CCNK O75909 1/20 0.43
▸ CCNA2 P20248 1/20 0.43
▸ CDK12 Q9NYV4 1/20 0.43
▸ CCNB2 O95067 1/20 0.43
▸ CCNE2 O96020 1/20 0.43
▸ CDK5 Q00535 1/20 0.43
▸ CDK5R1 Q15078 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30906794 1.00 CDK2 (0.61) CDK2CCNE1CDK1CCNB1CDK4
SCHEMBL27213195 0.91 CCNE1 (0.55) CDK2CCNE1CDK1CCNB1CDK4
SCHEMBL30906851 0.91 CCNE1 (0.55) CDK2CCNE1CDK1CCNB1CDK4
SCHEMBL30906882 0.90 CCNE1 (0.58) CDK2CCNE1CDK1CCNB1CDK4
SCHEMBL27213199 0.90 CCNE1 (0.58) CDK2CCNE1CDK1CCNB1CDK4
SCHEMBL30906844 0.89 CCNE1 (0.50) CDK2CCNE1CDK1CCNB1CDK4
SCHEMBL27213218 0.89 CCNE1 (0.50) CDK2CCNE1CDK1CCNB1CDK4
SCHEMBL30906898 0.89 CCNE1 (0.50) CDK2CCNE1CDK1CCNB1CDK4
SCHEMBL30906770 0.89 CDK2 (0.50) CDK2CCNE1CDK1CCNB1CDK4
SCHEMBL27213169 0.89 CDK2 (0.50) CDK2CCNE1CDK1CCNB1CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150340-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED 2024-05-09 — — US claimed
WO-2024077216-A1 CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED (US) 2024-04-11 — — WO claimed
US-20240150340-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED 2024-05-09 — — US disclosed
WO-2024077216-A1 CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED (US) 2024-04-11 — — WO disclosed
WO-2024077216-A1 CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED (US) 2024-04-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150340-A1 CDK Inhibitors And Their Use As Pharmaceuticals CDK6, CDK1, CDK3 CDK2 4/4885CCNE1 36/4885CDK1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback